If you have recently searched for exas stock on your brokerage platform, you were likely met with a flatlined chart, a frozen price of around $105.00, or a notice that the ticker has been suspended. This is not a glitch. On Monday, March 23, 2026, Abbott Laboratories (NYSE: ABT) officially completed its historic $21 billion acquisition of Exact Sciences Corporation (NASDAQ: EXAS), bringing an end to one of the most remarkable independent runs in the modern diagnostics sector.

For more than two decades, Exact Sciences was a titan of precision oncology, best known for its flagship non-invasive colon cancer screening test, Cologuard. However, as of late March 2026, EXAS stock has been officially delisted from the Nasdaq. This massive transition has left retail investors, former shareholders, and employees with a flurry of questions about cash payouts, tax implications, and how to continue investing in the future of cancer diagnostics.

This comprehensive guide will break down everything you need to know about the finalization of the Abbott-Exact Sciences merger, what happened to your EXAS stock, the tax strategies you must consider to avoid a 2026 financial headache, and how to position your portfolio for the next phase of the precision oncology boom.

The $21 Billion Deal: How Exact Sciences Merged with Abbott

The merger between Abbott and Exact Sciences represents the largest medtech transaction in years, signaling a major consolidation in the multi-billion-dollar cancer screening industry.

The Deal Timeline

• November 20, 2025: Abbott and Exact Sciences announce a definitive agreement under which Abbott will acquire Exact Sciences in an all-cash transaction valued at $105.00 per share.
• February 20, 2026: Exact Sciences stockholders overwhelmingly approve the merger at a special meeting, with over 99% of votes cast in favor of the transaction.
• March 19, 2026: The companies receive all remaining international and domestic regulatory clearances.
• March 23, 2026: The merger officially closes. Badger Merger Sub I, Inc., a wholly owned subsidiary of Abbott, merges into Exact Sciences, making it a direct, wholly owned subsidiary of Abbott. EXAS stock is officially halted and delisted.

The Strategic Rationale: Why Abbott Bought EXAS

For Abbott, acquiring Exact Sciences was a strategic masterstroke to capture a dominant share of the global cancer diagnostics market, which is estimated to be worth more than $60 billion. Exact Sciences brings an industry-leading portfolio, including Cologuard, the newly launched Cologuard Plus, Oncotype DX breast and colon recurrence tests, and a robust pipeline for multi-cancer early detection (MCED) and molecular residual disease (MRD) monitoring.

While Exact Sciences possessed world-class R&D and clinical data, it faced commercial scaling hurdles. Abbott’s massive global footprint, established relationships with healthcare systems worldwide, and dominant primary care salesforce provide the perfect engine to accelerate Cologuard’s international rollout and expand clinical access. Abbott expects the acquisition to add roughly $3 billion in incremental diagnostics sales in 2026 alone.

What Happens to My EXAS Stock? An Investor’s Checklist

Now that the merger has closed and the corporate restructuring is complete, the treatment of your EXAS stock depends entirely on how you held the shares. Below is the step-by-step breakdown of how different holdings are being processed in mid-2026.

1. Standard Brokerage Accounts (Fidelity, Schwab, Robinhood, etc.)

If you owned common shares of exas stock in a standard taxable brokerage account, you do not need to take any action. At the effective time of the merger, your shares were automatically cancelled and converted into the right to receive $105.00 in cash per share, without interest and subject to any applicable tax withholdings.

Depending on your broker, this cash balance should have cleared and settled in your account within 1 to 5 business days after March 23, 2026. The capital gains or losses will be reported on your 1099-B form for the 2026 tax year.

2. Shares Held in 401(k) Plans and IRAs

For retail investors or Exact Sciences employees holding stock in a tax-advantaged account like a Traditional or Roth IRA, or the company’s Fidelity 401(k) plan, the mechanics are similar but the tax consequences differ.

• Your shares were converted to cash at the $105.00 rate.
• Because these holdings are inside a tax-sheltered vehicle, this conversion does not trigger an immediate capital gains tax liability.
• Inside the company 401(k) plan, default rules typically sweep these cash proceeds into a target-date fund corresponding to your projected retirement age. Later in 2026, the Exact Sciences 401(k) accounts at Fidelity are scheduled to consolidate into Abbott’s master retirement plan managed by UBS. It is highly recommended that you log in to review your current asset allocation and rebalance according to your risk tolerance.

3. Employee Equity: RSUs, PSUs, and the ESPP

For Exact Sciences employees, the cash transaction represents a major liquidity event, often dubbed the "windfall year," but it also presents a highly complex financial planning scenario.

• Vested Shares: Treated exactly like common stock—converted to cash at $105.00 per share.
• Unvested Restricted Stock Units (RSUs) & Performance Stock Units (PSUs): Under the terms of the merger proxy, unvested equity awards granted prior to November 19, 2025, were subject to "double-trigger" or accelerated single-trigger vesting upon the close of the deal. These accelerated RSUs and PSUs were fully vested, cancelled, and converted into cash at $105.00 per share, net of ordinary income tax withholding.
• Post-Announcement RSUs: Any RSUs granted on or after November 19, 2025, were not cashed out immediately. Instead, they were assumed by Abbott and converted into replacement Abbott RSU awards of equivalent value, maintaining their original vesting schedules (typically vesting in four equal annual installments starting in February 2027).

4. Convertible Senior Notes

Exact Sciences had several outstanding tranches of convertible senior notes due between 2027 and 2031. Following the merger, these debt instruments have been modified. Each $1,000 in principal amount of these notes is now convertible solely into cash, calculated using the note's applicable conversion rate multiplied by the $105.00 buyout price.

Navigating the "Tax Cliff": Key Implications of the Cash Buyout

While a premium payout is great news, the transition of exas stock into cash is a taxable event for standard brokerage accounts. Unlike stock-for-stock mergers (which are often structured as tax-free reorganizations), an all-cash merger forces you to realize capital gains in the year the deal closes.

Calculating Your Capital Gains Tax

Your taxable gain (or loss) is calculated as:

$$\text{Taxable Gain/Loss} = ($105.00 \times \text{Number of Shares}) - \text{Total Cost Basis}$$

If you held your EXAS shares for longer than one year prior to March 23, 2026, your profits will be taxed at preferential long-term capital gains rates (0%, 15%, or 20%, depending on your taxable income, plus the 3.8% Net Investment Income Tax for high earners). If you held the shares for one year or less, the profits are taxed as short-term capital gains at your ordinary federal income tax rates.

The Employee Tax Spike of 2026

For Exact Sciences employees, the accelerated vesting of RSUs and PSUs is treated as ordinary compensation income, not capital gains. This income is subject to federal, state, and payroll tax withholdings at the time of the merger close.

Because a large amount of equity vested all at once on March 23, 2026, many employees are facing a massive "tax cliff". This sudden influx of ordinary income can easily push you into a higher federal income tax bracket (such as the 35% or 37% bracket) and trigger the phase-out of various tax deductions and credits.

Actionable Tax-Reduction Strategies for 2026

If you are facing a significant tax bill from the EXAS cash buyout, consider the following strategies to offset your 2026 tax liability:

1. Utilize a Donor-Advised Fund (DAF): If you are charitably inclined, you can deposit a portion of your cash windfall into a DAF. This allows you to take an immediate tax deduction in 2026 to offset your high-income year, while distributing the funds to your favorite charities over many years.
2. Max Out Tax-Advantaged Accounts: Ensure you are contributing the absolute maximum allowed to your pre-tax 401(k), Health Savings Account (HSA), and Traditional IRA to lower your Adjusted Gross Income (AGI).
3. Tax-Loss Harvesting: Look through your taxable brokerage accounts for underperforming assets. Selling losing positions before December 31, 2026, will generate capital losses that can directly offset the capital gains realized from your EXAS stock payout.
4. Bunch Deductions: If you typically take the standard deduction, consider "bunching" itemized deductions (such as prepaying property taxes or making large charitable gifts) into the 2026 tax year to surpass the standard deduction threshold and maximize your write-offs.

The Next-Gen Oncology Battle: Why Abbott Wanted Cologuard Plus

To understand why Abbott paid a premium for Exact Sciences, we have to look closely at the underlying clinical assets. The crown jewel of the transaction is Cologuard Plus, the next-generation multi-target stool DNA test that Exact Sciences launched commercially in early 2025.

Cologuard Plus: Setting a New Clinical Standard

Approved by the FDA in late 2024 and fully launched in 2025, Cologuard Plus utilizes a refined panel of novel DNA biomarkers, enhanced laboratory chemistry, and superior sample stability to address the primary limitation of the original Cologuard test: its false-positive rate.

Data from the landmark BLUE-C study—a prospective, head-to-head trial involving over 20,000 average-risk individuals—demonstrated the clinical superiority of Cologuard Plus:

• 95% Sensitivity for detecting colorectal cancer overall (compared to only 71% for standard fecal immunochemical tests, or FIT).
• 43% Sensitivity for advanced precancerous lesions, helping catch disease before it turns malignant.
• 94% Specificity, representing an approximate 40% reduction in false-positive results compared to the legacy Cologuard test.

By significantly reducing false positives, Cologuard Plus reduces the burden of unnecessary follow-up colonoscopies on the healthcare system while maintaining exceptional cancer-detection rates.

The Rising Competitive Threats

Despite Cologuard Plus’s clinical excellence, the competitive landscape in non-invasive colorectal cancer screening is intensifying, which likely influenced Exact Sciences' decision to seek the shelter of a larger parent company.

1. Geneoscopy’s ColoSense: Approved by the FDA in May 2024, ColoSense is the first non-invasive, stool-based multi-target RNA (mt-sRNA) screening test. Because it measures RNA rather than DNA, it is not subject to age-related methylation patterns. In its pivotal CRC-PREVENT trial, ColoSense demonstrated 93% sensitivity for colorectal cancer and 45% sensitivity for advanced adenomas. Crucially, it showed 100% sensitivity in the emerging 45-49 age cohort, making it a formidable direct competitor to Cologuard Plus.
2. Guardant Health’s Shield: Approved by the FDA in July 2024, Shield is a blood-based colorectal cancer screening test. While blood-based tests (liquid biopsies) historically have lower sensitivity for precancerous lesions than stool-based tests, they offer exceptionally high patient compliance.

By integrating with Abbott, the Cologuard franchise gains access to the Abbott Nexus platform and its vast primary care network, allowing it to defend its market share against emerging stool RNA and liquid biopsy competitors.

How to Invest in the "New" Exact Sciences: ABT Stock Analysis

With EXAS stock no longer trading on public markets, investors who still believe in the growth story of Cologuard Plus, Cancerguard, and precision oncology have a clear choice: they must look to Abbott Laboratories (NYSE: ABT).

Evaluating Abbott (NYSE: ABT) as an Investment

Transitioning your investment from a pure-play, high-growth, unprofitable diagnostics company (EXAS) to a highly diversified, profitable global healthcare conglomerate (ABT) fundamentally changes your risk profile.

• Diversification and Stability: Abbott operates across four major divisions: Medical Devices (led by the FreeStyle Libre diabetes monitoring system), Established Pharmaceuticals, Nutritionals (Similac), and Diagnostics. The Exact Sciences portfolio will be housed inside Abbott’s Rapid Diagnostics and Molecular Diagnostics division, immediately elevating Abbott's oncology screening capabilities.
• Financial Profile: While Exact Sciences struggled to consistently generate net income—posting a net loss of $208 million on $3.25 billion in revenue for FY2025—Abbott is a cash-generating machine. Abbott brings an annual free cash flow of over $7 billion, giving it the capital required to aggressively fund R&D for Exact Sciences' pipeline assets like Oncodetect (MRD) and Cancerguard (MCED).
• Dividend Growth: Unlike EXAS, which never paid a dividend, Abbott is a storied Dividend King. Abbott has increased its dividend payout for more than 50 consecutive years, offering a reliable income stream alongside capital appreciation.
• Near-Term Dilution, Long-Term Accretion: In its early 2026 earnings updates, Abbott projected that the Exact Sciences acquisition would contribute approximately $0.20 of adjusted diluted EPS dilution for the full year of 2026 due to integration costs and transaction-related expenses. However, management expects the acquisition to become highly accretive to organic sales growth and gross margins starting in late 2027 as duplicate administrative costs are eliminated and global commercial synergies take hold.

If you enjoyed the high-beta, volatile swings of EXAS stock, ABT stock will feel much more conservative. However, it offers a much safer, dividend-backed vehicle to participate in the long-term secular growth of early cancer detection.

Frequently Asked Questions (FAQs)

Can I still buy EXAS stock?

No. Exact Sciences was officially acquired by Abbott Laboratories on March 23, 2026, and its common shares were delisted from the Nasdaq. You can no longer purchase EXAS shares on any public stock exchange.

What happens if I still hold physical stock certificates for Exact Sciences?

If you possess physical paper stock certificates for EXAS, they no longer represent equity in the company. You must contact Exact Sciences’ designated paying agent (typically Computershare or the transfer agent listed in the merger proxy) to surrender your physical certificates in exchange for the cash payout of $105.00 per share, less any applicable taxes.

Why did the stock price stop at $104.91 instead of exactly $105.00 before closing?

In the days leading up to the final closing on March 23, 2026, EXAS stock traded at a very slight discount to the $105.00 buyout price (often closing around $104.91). This minor gap represents the "merger arbitrage spread," which reflects the time-value of money and the microscopic risk that the deal might fail to close at the very last second. Once the merger closed, all remaining shares were converted to the full $105.00 cash value.

Is there a way to roll over my EXAS cash payout tax-free?

If your EXAS shares were held in a taxable brokerage account, the cash payout is automatically considered a taxable sale, and you cannot roll it over tax-free. However, if your shares were held inside a tax-advantaged account like an IRA or 401(k), the cash remains tax-sheltered, and you can freely reinvest it into other equities or funds within that account without triggering any capital gains taxes.

Who is the main competitor to Cologuard and Abbott in non-invasive screening?

Following the merger, Abbott's primary competitors in the non-invasive colorectal screening space are Geneoscopy, which produces the FDA-approved ColoSense stool RNA test, and Guardant Health, which manufactures the FDA-approved Shield blood test.

Conclusion: The End of an Era, the Start of a Diagnostics Giant

The retirement of the exas stock ticker marks the end of a legendary chapter in biotechnology history. From a micro-cap company trading below $5.00 a share during its darkest days in 2015, Exact Sciences persevered to become a household name in medical diagnostics, ultimately delivering a massive $21 billion exit to its loyal shareholders.

For former investors, the immediate focus must shift to tax planning to mitigate the impact of the cash payout on your 2026 tax returns, particularly if you are an employee dealing with accelerated equity vesting.

Looking forward, the spirit and technology of Exact Sciences live on. By transitionally shifting capital into Abbott Laboratories (NYSE: ABT), you can continue to support the mission of early cancer detection while enjoying the stability, cash flow, and dividend security of one of the world's most robust healthcare giants.